BRAF and non-small cell lung carcinoma: While one NSCLC patient was treated with combined BRAF and MEK inhibition due to the identification of a BRAF V600E mutation, four patients with NSCLC showed an aberration in EGFR (either EGFR Del19 or EGFR L858R) and were treated with osimertinib (Figure 2A and Supplementary Figure S6A).